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ABSTRACT
Epithelial-to-mesenchymal transition (EMT) is a process known to be 
associated with aggressive tumor behavior, metastasis and treatment resistance. 
It is characterized by coincidental upregulation of mesenchymal markers such as 
vimentin, fibronectin and N-cadherin concurrent with E-cadherin downregulation. 
Studies on EMT are generally performed in cell lines and mouse models, while the 
histopathological and phenotypical properties in clinical prostate cancer (PCa) are 
still unclear. 
The objective of this study was to identify EMT in PCa patients. We demonstrated 
that N-cadherin, vimentin and fibronectin were generally not co-expressed in 
corresponding tumor regions. Immunofluorescent double stainings confirmed that 
co-expression of mesenchymal markers was uncommon, as we found no prostate 
cancer cells that co-expressed N-cadherin with fibronectin and only rare (<1%) 
cells that co-expressed N-cadherin with vimentin. Downregulation of E-cadherin was 
demonstrated in all N-cadherin positive tumor cells, but not in vimentin or fibronectin 
positive tumor cells. We further analyzed N-cadherin expression in morphologically 
distinct PCa growth patterns in a radical prostatectomy cohort (n = 77) and found 
that N-cadherin is preferentially expressed in ill-defined Gleason grade 4 PCa. In 
conclusion, we demonstrate that N-cadherin is the most reliable marker for EMT in 
clinical PCa and is preferentially expressed in ill-defined Gleason grade 4 growth 
pattern.
INTRODUCTION
The grade of differentiation in clinical PCa 
according to the modified Gleason scoring system is 
one of the most important predictive factors for disease 
behavior and therapeutic decision-making [1-3]. The 
Gleason grading system is solely based on architectural 
tumor growth patterns. While Gleason grade 1-3 PCa is 
composed of well-delineated malignant glands, various 
growth patterns classify as Gleason grade 4, such as ill-
defined, fused, glomeruloid and cribriform (Figure 1) [1-
3]. Despite the widespread application of Gleason grading 
in clinical practice, little is known on the molecular 
background of specific Gleason grade growth patterns.
Understanding the molecular-biological processes 
by which tumor cells invade surrounding tissues and 
metastasize to distant sites, is an ongoing challenge 
in cancer research, as metastasis is the major cause of 
death for cancer patients. Metastasis requires cells to 
loose cellular connections and become migratory, which 
can be driven by the process of EMT [4]. Expression of 
E-cadherin (cadherin-1) is the keystone of epithelial cell 
state and is downregulated during EMT [4]. In many 
carcinomas including PCa, EMT is associated with 
invasive and aggressive behavior, metastasis to distant 
locations and treatment resistance [5-11]. Especially 
the shift from E-cadherin to N-cadherin (cadherin-2) 
expression correlates with cancer progression and 
metastasis [12-17].
While EMT in PCa has mainly been studied in cell 
line models, the morphological and phenotypic substrate 
of EMT in PCa patients is still unclear. In colon carcinoma, 
cancer cells undergoing EMT are characterized by spindle-
shaped morphology similar to in vitro studies [18]. In 
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conventional clinical PCa, however, spindle-shaped tumor 
cells are not observed and thus the morphological substrate 
of EMT is still unclear in these tumors. The aim of this 
study was to investigate the morphology and location of 
EMT in clinical PCa. We demonstrate for the first time that 
EMT in PCa is characterized by N-cadherin expression in 
morphologically ill-defined Gleason grade 4 PCa glands.
RESULTS
EMT marker expression in benign and malignant 
prostate epithelium
While EMT in cell culture models is characterized 
by simultaneous up- and downregulation of markers 
such as vimentin, N-cadherin and E-cadherin, it is not 
known whether synchronous expression also occurs 
within cell populations undergoing EMT in clinical 
PCa. First, we studied the expression of EMT markers 
vimentin, fibronectin, N-cadherin and E-cadherin in a set 
of 23 radical prostatectomy (RP) specimens to determine 
which marker is most representative for EMT in clinical 
specimens and whether EMT markers were co-expressed 
within the same tumor areas. The clinicopathologic 
features of the cohort (primary set) are shown in Table 1. 
Cytoplasmic vimentin was abundantly, although 
not homogeneously, expressed in normal fibromuscular 
prostate stroma of all patients, as well as in sporadic 
benign luminal epithelial cells of patients (22/23, 96%) 
(Table 2). In benign epithelium, only one case (1/23, 
4%) demonstrated complete absence of vimentin 
expression. Vimentin expression in benign epithelium 
Figure 1: Gleason grade growth patterns of clinical prostate cancer. Gleason grade 3 (GG3) consists of well-delineated round 
to ellipsoid tumor glands. Gleason grade 4 (GG4) comprises the following growth patterns: ill-defined, fused, glomeruloid and cribriform. 
Gleason grade 5 (GG5) shows a solid tumor growth pattern or growth in single cells and cords (20x, original magnification).
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was positive in < 1% of luminal cells in the majority of 
patients (18/23, 78%), while expression in 1-4% or > 4% 
-10% of luminal cells occurred in 2/23 (9%) cases each. 
Vimentin expression was observed in 9/23 (39%) PCa 
specimens (Table 2); 7 tumors showed expression in < 
1% of malignant cells (30%) and 2 cases in between 1% 
and 4% of malignant cells (9%). In most tumors (14/23; 
61%), however, no vimentin expression was observed. The 
percentage of vimentin positive cells in benign epithelium 
was significantly higher than in PCa (p < 0.001). 
Fibronectin was abundantly expressed in the 
cytoplasm of prostate stromal cells and in < 1% of benign 
luminal epithelial cells (22/23, 96%) (Table 2). In PCa 
tissues, expression of fibronectin occurred most frequently 
in < 1% of tumor cells (19/23, 82%), while 2 cases were 
entirely negative (2/23, 9%) or showed expression in > 
4%-10% of PCa cells (2/23; 9%) (Table 2). Expression 
of fibronectin was not statistically different in benign and 
malignant prostate epithelium (p = 0.28).
N-cadherin was expressed in all nerve fibers, which 
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Figure 2: Mesenchymal EMT markers are not expressed in corresponding regions in clinical PCa. Consecutive slides 
were stained for EMT markers: E-cadherin, N-cadherin, vimentin and fibronectin. Tumor areas positive for N-cadherin were negative for 
vimentin and fibronectin (panel A and B). Vimentin (panel C) and fibronectin (panel D) positive tumor areas also did not co-express any of 
the other EMT markers (20x, original magnification). Overview slides demonstrate Gleason score 3+4 = 7 (ill-defined; panel A, B), 3+4=7 
(fused; panel C) and 4+3 = 7 (cribriform; panel D). 
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served as positive internal control in all cases. Expression 
in < 1% of benign luminal epithelial cells was present 
in 12/23 samples (52%), while the remaining cases 
were entirely negative (11/23, 48%) (Table 2). In PCa, 
N-cadherin expression was absent in 10 cases (44%) or 
present in < 1% (9/23, 39%), 1%-4% (1/23, 4%) or > 
4%-10% (3/23, 13%) of PCa cells (Table 2). Expression 
of N-cadherin was statistically similar in benign and 
malignant prostate epithelium (p = 0.21), although 
high expression ( > 1-10%) was exclusive to malignant 
epithelium. None of the EMT markers showed expression 
in more than 10% of benign or malignant epithelial cells. 
Comparison of vimentin, fibronectin and N-cadherin 
expression patterns in consecutive PCa sections did not 
reveal overlap of staining within corresponding areas 
(Figure 2). A hallmark event of EMT is downregulation of 
E-cadherin in epithelial cells. Areas with a complete loss 
of E-cadherin were not identified immunohistochemically 
in any case (0/23), although focal variation in expression 
intensity was observed. 
Immunofluorescent co-expression analysis of 
EMT markers
To verify that EMT markers vimentin, fibronectin 
and N-cadherin were not expressed within the same 
cell population, we performed immunofluorescent co-
expression analysis in PCa samples (Figure 3). Vimentin 
did not co-localize with fibronectin (Figure 3A). In only 
one patient, < 1% of N-cadherin positive PCa cells were 
also positive for vimentin, while the vast majority of 
N-cadherin positive cells were vimentin negative (Figure 
3B). Co-localization of fibronectin and N-cadherin was not 
observed (Figure 3C). Therefore, vimentin, fibronectin and 
N-cadherin were generally expressed in independent cell 
populations. 
To determine which of the markers was most 
representative for EMT in clinical specimens, we 
performed immunofluorescent co-expression analysis 
with E-cadherin (Figure 4). Downregulation of E-cadherin 
was seen in all malignant cell clusters that expressed 
N-cadherin, indicative of cadherin switching (Figure 
Figure 3: Mesenchymal EMT markers are not co-expressed in clinical PCa. Immunofluorescent double stainings demonstrated 
that vimentin (Vim) and fibronectin (Fibro) were not co-expressed (panel A). Vimentin positive PCa cells were fibronectin negative 
(arrowhead) and vice versa (arrow). N-cadherin (N-cad) was neither co-expressed with vimentin (panel B) or fibronectin (panel C). Original 
magnifications 100x (A) and 63x (B, C). Scale bar = 10µm.
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4A) [15, 19]. E-cadherin expression was high in the 
majority of vimentin positive PCa cells (Figure 4B). 
In a subpopulation (circa 10%) of vimentin positive 
tumor cells, however, E-cadherin was slightly decreased 
(Figure 4C). None of the fibronectin positive PCa cells 
showed E-cadherin downregulation (Figure 4D). Since 
expression of N-cadherin coincided with vast E-cadherin 
downregulation, N-cadherin was considered the most 
reliable mesenchymal marker for EMT in clinical PCa. 
N-cadherin expression in clinical PCa
EMT is preferentially occurring at the invasive 
front of various human cancers, such as oral squamous 
cell carcinoma and colorectal adenocarcinoma [20, 21]. 
In these tumor types, EMT is characterized by a spindle-
like morphology of tumor cells and gain of mesenchymal 
markers. Spindle-shaped tumor cells, however, are not 
pathologically recognized in conventional PCa. To 
Figure 4: E-cadherin is downregulated in N-cadherin positive tumor cell clusters in clinical PCa. Immunofluorescent 
double stainings showed E-cadherin (E-cad) downregulation in N-cadherin (N-cad) positive cell clusters (arrowhead) (panel A). N-cadherin 
negative cells demonstrated normal E-cadherin levels at the membrane (arrow). Vimentin (Vim) positive PCa cells generally expressed 
normal levels of E-cadherin (arrowheads) (panel B), although E-cadherin was downregulated in some vimentin positive cells (arrowheads) 
(panel C). Fibronectin (Fibro) positive PCa cells expressed similar E-cadherin levels (arrowhead) as fibronectin negative PCa cells (arrow) 
(panel D). Original magnifications 63x (A-C) and 100x (D). Scale bar = 10µm.
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determine whether EMT as identified by N-cadherin 
expression was also related to a specific growth pattern 
in clinical PCa, we quantified its expression in distinctive 
PCa growth patterns, as defined by the WHO 2009, in a 
set of 77 RP specimens (Figure 1) [1-3]. Expression of 
N-cadherin occurred significantly more frequent in ill-
defined (27/70, 39%) than in fused (3/50, 6%; p < 0.001) 
or cribriform (2/29, 7%; p = 0.001) Gleason grade 4 PCa 
(Table 3). Although N-cadherin expression occurred more 
often in ill-defined PCa (27/70, 39%) than in glandular 
Gleason grade 3 (21/75, 28%; p = 0.22), glomeruloid 
Gleason grade 4 (2/10, 20%; p = 0.31), solid fields (0/4, 
0%; p = 0.29), cords and single cells (2/8, 25%; p = 
0.70) Gleason grade 5 PCa, the difference did not reach 
statistical significance. However, the overall percentage 
of N-cadherin positive cells was significantly higher in 
ill-defined glands (median 10%; range 1-100%) than in 
Gleason grade 3 (median 1%; range 1-5%; p < 0.001) 
PCa. Due to the low number of N-cadherin positive fused 
(n = 3), glomeruloid (n = 2), solid fields (n = 0), cords 
and single cells (n = 2) PCa growth patterns, statistical 
analysis was not performed in these cases. Expression of 
N-cadherin was neither confined to the tumor boundary 
(invasive front) nor enriched in extra-prostatic (pT3) 
disease (p = 0.16). 
DISCUSSION
EMT is an important biological process in 
embryogenesis, tissue homeostasis and tumor progression. 
It has been extensively studied in clinical colorectal 
cancer, where it is recognized as spindle-shaped tumor 
cells within desmoplastic stroma at the invasive front 
[18, 22-24]. Studies on EMT in human prostate tissues 
generally encompass immunohistochemical analysis of 
single markers such as E-cadherin, N-cadherin, β-catenin, 
fibronectin, Slug, Snail, Twist, vimentin, ZEB1 and ZEB2 
in relation to clinicopathologic features including death of 
disease and metastasis [12, 19, 25-30]. 
Various groups have pointed at the importance of 
EMT and N-cadherin expression for the progression 
of clinical PCa [7, 19, 25, 26, 31, 32]. Expression 
of N-cadherin has been found in 0% up to 54% of 
PCa patients [19, 26, 27]. We found that 48% of PCa 
expressed N-cadherin, which is in line with other reports. 
Similar to previous studies, we have demonstrated that 
E-cadherin, a key EMT marker, was downregulated in 
N-cadherin positive tumor cells, which is often referred 
to as cadherin switching [12, 19]. In this study, we found 
that EMT as identified by N-cadherin expression occurred 
preferentially in ill-defined PCa glands. Ill-defined 
PCa glands correspond to tumor glands with irregular 
outline and are considered a subtype of modified Gleason 
grade 4 PCa [1]. While we also found expression in 
glandular Gleason 3, the median percentage of positive 
N-cadherin cells was significantly lower as compared to 
ill-defined glands. As ill-defined modified Gleason grade 
4 PCa glands have an irregular contour and are strongly 
associated with immunohistochemical cadherin switching, 
they putatively represent the morphological substrate of 
EMT in clinical PCa. 
Although N-cadherin overexpression occurred 
preferentially in Gleason grade 4 ill-defined growth 
pattern, a significant number of ill-defined structures did 
not express N-cadherin. It is possible that other cadherins 
such as OB-cadherin (cadherin-11) are upregulated in 
these prospective EMT regions [33, 34]. EMT has also 
been implicated to play a role in therapy resistance [6, 
35, 36]. Expression of mesenchymal markers including 
vimentin and fibronectin was increased and E-cadherin 
was decreased upon androgen deprivation in PCa patients 
[6, 35]. Antibodies directing against N-cadherin inhibited 
tumor growth, metastasis and castration resistance of 
PCa cells in xenografted mice [36]. Since the stromal 
and inflammatory background in lymph node and bone 
metastasis is different from prostate stroma, in this study 
we specifically set out to investigate EMT in the context 
of its naive prostate background. 
Although N-cadherin, vimentin and fibronectin 
are generally all considered as EMT markers, we found 
that they label independent cell populations in clinical 
specimens. Vimentin was regularly expressed both in 
benign epithelial glands and PCa with intact membranous 
E-cadherin, indicating vimentin expression does not 
necessarily confer mesenchymal properties to human 
prostate epithelial cells. Others have also demonstrated 
the abundant expression of vimentin in benign prostate 
epithelium and other epithelial cells including liver, 
kidney, vocal cords and breast [37-43]. Although 
fibronectin is an important EMT marker especially in in 
vitro studies, little is known about fibronectin expression 
in clinical cancers [44-49]. Expression and secretion of 
fibronectin allows cells to alter the extracellular matrix 
through the activation of matrix metalloproteinases and 
aid in migration [50, 51]. We showed that fibronectin is 
expressed in only a small percentage of tumor cells that 
co-expressed E-cadherin, which argues against fibronectin 
as a marker for EMT in clinical specimens. Taken together, 
the role of vimentin and fibronectin as markers of EMT is 
less straightforward in clinical PCa than in vitro. 
A novel approach in our study was the investigation 
of molecular markers in relation to specific growth 
patterns instead of more general Gleason grades. Gleason 
grade 4 PCa encompasses a heterogeneous group of tumor 
growth patterns such as ill-defined, fused, glomeruloid 
and cribriform. While the vast majority of clinical and 
biological studies regard Gleason grade 4 PCa as a uniform 
tumor entity, we believe that discrimination of individual 
growth patterns adds new information to research 
analysis and facilitates comprehensive interpretation of 
research data. Recently, we and others have shown that 
cribriform growth in Gleason score 7 PCa is a strong 
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independent adverse parameter for distant metastasis 
and disease-specific death after RP [52, 53]. Qian et al. 
demonstrated a copy number amplification of c-MYC in 
cribriform Gleason grade 4 PCa, but not in other Gleason 
grade 4 subtypes [54]. In this study, we demonstrate that 
N-cadherin expression preferentially occurs in ill-defined 
Gleason grade 4 PCa, indicating that this specific growth 
pattern is representing biological EMT in clinical PCa. 
Therefore, taking individual Gleason grade 4 growth 
patterns into account adds value to the interpretation of 
both clinical and biological PCa studies. 
A potential bias in our study is the fact that our RP 
specimens represent a selection of intermediate risk PCa. 
In our institute, RP is not the first choice of therapy for a 
large number of patients with limited Gleason score 6 PCa 
on biopsy or with extensive high-risk disease. Since our 
population included a set of consecutive RP specimens not 
all growth patterns are represented equally. Although our 
study included the most prevalent PCa growth patterns, 
it cannot be excluded that the morphological substrate of 
EMT in pure Gleason grade 3 or less frequent Gleason 
grade 5 patterns is different than found in the current 
study. Finally, EMT refers to a dynamic process of cell 
transformation. Cadherin-switching is an important step in 
EMT, but it is unclear whether cadherin switching marks 
the entire or just a specific part of the dynamic EMT 
process.
In conclusion, we found that commonly used 
EMT markers vimentin, fibronectin and N-cadherin 
are not co-expressed within the same cell populations 
in clinical PCa. Since E-cadherin is downregulated in 
tumor cells expressing N-cadherin but not vimentin 
or fibronectin, cadherin switching represents the best 
marker of EMT in PCa patients. N-cadherin expression 
occurred preferentially in ill-defined Gleason grade 4 
PCa, indicating that this specific growth pattern is the 
morphological substrate of EMT in clinical PCa. 
MATERIALS AND METHODS
Clinical specimens
RP specimens were all retrieved from the archive 
of the department of pathology, Erasmus Medical 
Centre, Rotterdam, The Netherlands. All RP’s had been 
performed in our institute between July 2010 and May 
2013, prompted by histologically proven hormone-naïve 
PCa on diagnostic needle-biopsy. After receipt of RP 
specimens at the department of pathology, a transverse 
tissue slice was frozen in liquid nitrogen for research 
purposes. After thorough injection of 4% neutral-
buffered formalin to allow for fast and equal fixation of 
RP specimens, the prostate was pinned to a cardboard to 
avoid tissue retraction. After additional fixation overnight, 
RP specimens were sliced transversally from apex to basis 
in 4 mm slices and completely embedded for pathologic 
analysis. At pathologic evaluation by a urogenital 
pathologist (GvL), modified Gleason score, extra-prostatic 
extension, seminal vesicle and bladder neck involvement, 
pT-stage (WHO 2009) and surgical margin status were all 
recorded. We included a primary set of 23 RP specimens 
and an extended set of 77 RP specimens. The primary set 
(N = 23) was used to broadly analyse the expression of 
EMT-associated markers vimentin, fibronectin, E- and 
N-cadherin, and determine whether respective markers 
were co-expressed in the same area. The extended set 
(N = 77) was an extension of the primary RP set (N = 
23) with 44 novel cases and was used to statistically 
relate the occurrence of EMT in well-described prostate 
cancer growth patterns. Use of RP specimens for research 
purposes was approved by the Erasmus MC Medical 
Ethics Committee (MEC-2011-295 and 296; August 25th, 
2011) and is in accordance with the Helsinki Declaration 
of 1975, as revised in 1983.
Immunohistochemistry
Five µm slices were cut and mounted on 
aminoacetylsilane coated glass slides (Starfrost, Berlin, 
Germany). Slides were deparaffinized in xylene and 
rehydrated in decreasing ethanol steps. Endogenous 
peroxidase was blocked in 1% hydrogen peroxide in 
Phosphate Buffered Saline (PBS) for 20 min. Antigen 
retrieval was performed with TRIS (hydroxymethyl) 
aminomethane-EDTA (pH 9.0, Klinipath, Duiven, The 
Netherlands) in a microwave (MicroMed T/T Mega, 
Milestone, Sorisole, Italy) for 15 min. Slides were 
incubated overnight at 4°C with primary antibodies 
targeting N-cadherin (1:50, clone 6G11, Dako, Glostrup, 
Denmark), vimentin (1:500, clone Vim3B4, Dako, 
Glostrup, Denmark), fibronectin (1:500, ab2413, Abcam, 
Cambridge, U.K.) or E-cadherin (1:200, clone NCH-38, 
Dako, Glostrup, Denmark) diluted in phosphate-buffered 
normal antibody diluent (Immunologic, Duiven, The 
Netherlands). The specificity of all antibodies had been 
verified using Western blot analysis (data not shown). 
Secondary antibodies were incubated for 30 min. at 
room temperature and chromogenic visualization was 
performed with the EnVision Dako kit (Dako, Glostrup, 
Denmark). Slides were counterstained with haematoxylin, 
washed, dehydrated, cleared in xylene and mounted in 
Entellan® new (Merck Millipore, Billerica, U.S.A.). All 
immunohistochemical stainings included negative controls 
by omitting the primary antibody.
Immunohistochemical analysis
Immunohistochemical expression analysis was 
performed on consecutive PCa tissue sections of a 
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primary set of 23 RP specimens and an extended set 
of 77 RP’s. The primary set was used to determine 
general expression patterns of EMT markers vimentin, 
fibronectin, N-cadherin and E-cadherin. In this set, 
expression of respective proteins was determined in 
benign prostate epithelium, PCa and intervening stroma. 
N-cadherin was additionally scored in an extended set 
of RP specimens (n = 77) to examine its expression in 
specific PCa growth patterns [1-3]. The occurrence and 
relative percentage of individual PCa growth patterns were 
recorded in haematoxylin and eosin stained tissue slides 
by a urogenital pathologist (GvL). The following growth 
patterns were distinguished: “glandular”, defined as well-
delineated round to ellipsoid PCa glands, corresponding 
to Gleason grade 3; “ill-defined”, defined as PCa glands 
with an irregular outline; “fused”, defined as more or 
less complex PCa structures often with slit-like lumina 
with the vast majority of cells being adjacent to surround 
stroma; “cribriform”, defined as solid epithelial structures 
with punched-out lumina, with the majority of cells not 
contacting surrounding connective tissue; “glomeruloid”, 
defined as intra-glandular epithelial proliferations 
resembling renal glomeruli, all corresponding to Gleason 
grade 4; “single cells”, “cords” and “solid fields” all 
corresponding to Gleason grade 5 [1-3]. The percentage 
of N-cadherin positive tumor cells was semi-quantitatively 
estimated in all individual growth patterns present in one 
tissue section.
Immunofluorescence
Co-expression analysis of EMT markers was 
performed by immunofluorescent staining of 9 fresh 
frozen PCa samples. Sections of 5 µm thick for were 
cut at a cryostat, fixed with 4% formaldehyde solution 
(Klinipath, Duiven, The Netherlands) for 20 min. and 
permeabilised with 0.5% TritonX-100 in PBS for 10 min. 
Slides were air-dried for one hour at room temperature, 
washed with PBS, and incubated with combinations of 
mouse anti-N-cadherin (1:25, clone 6G11, Dako, Glostrup, 
Denmark), rabbit anti-N-cadherin (1:75, clone D4R1H, 
Cell Signaling Technology, Danvers, U.S.A.), mouse 
anti-vimentin (1:100, clone Vim3B4, Dako, Glostrup, 
Denmark), rabbit anti-vimentin (1:100, clone D21H3, 
Cell Signaling Technology, Danvers, U.S.A.), mouse 
anti-E-cadherin (1:50, clone NCH-38, Dako, Glostrup, 
Denmark) or rabbit anti-fibronectin (1:200, ab2413, 
Abcam, Cambridge, U.K.) in 1% bovine serum albumin 
(BSA) in PBS. The specificity of all antibodies had been 
verified using Western blot analysis and appropriate 
immunohistochemical controls (data not shown). After 
washing with PBS, slides were incubated with goat anti-
mouse Ig labelled with Alexa 488 (1:200, Molecular 
Probes, Eugene, U.S.A.) combined with goat anti-rabbit 
Ig labelled with Alexa 594 (1:200, Molecular Probes, 
Eugene, U.S.A.), or goat anti-rabbit Ig labelled with Alexa 
488 (1:200, Molecular Probes, Eugene, U.S.A.) combined 
with goat anti-mouse Ig labelled with Alexa 594 (1:200, 
Molecular Probes, Eugene, U.S.A.). Slides were mounted 
in Vectashield (Vector Laboratories, Peterborough, U.K.) 
containing Hoechst 34580 (1:4000, Life Technologies, 
Bleiswijk, The Netherlands) to visualize nuclei. 
Immunofluorescent tissue sections were analyzed using a 
confocal laser scanning microscope (Zeiss LSM 700, Carl 
Zeiss, Oberkochen, Germany) with ZEN 2012 imaging 
software (Carl Zeiss, Oberkochen, Germany).
Statistics
Comparison of EMT marker expression in benign 
prostate epithelium and PCa was analyzed using Pearson 
chi-square test. The frequency of N-cadherin expression 
in separate PCa growth patterns was compared using the 
Fisher’s exact test. The non-parametric Mann-Whitney 
U test was used to analyze the percentage of N-cadherin 
positive tumor cells in individual growth patterns. A 
p-value of ≤ 0.05 was considered statistically significant. 
Statistical analyses were performed using IBM SPSS 
Statistics 21 (IBM Corp, Armonk, U.S.A.).
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